---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-237191"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:37:03.074954+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma enters long-term supply agreement for neffy glass microvials through 2035

## Summary
- Upfront payment of €3 million to Nuova Ompi for glass microvial supply.
- Supplier must establish manufacturing force and capabilities to meet obligations.
- Annual minimum purchase quantities and capped annual price adjustments specified.
- Supply agreement expires December 31, 2035; termination for breach or reasonable business reasons.

## SEC filing metadata
- accession: 0001193125-24-237191
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312524237191/0001193125-24-237191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312524237191/d902443d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-237191
- JSON: https://secwatch.observer/filing/0001193125-24-237191.json
- Plain text: https://secwatch.observer/filing/0001193125-24-237191.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.